Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn's disease in the Kingdom of Saudi Arabia
{{output}}
Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects approximately 4.9 million individuals globally. Advanced therapies have significantly improved IBD management; how... ...
